MedPath

Evaluation of TaiHao Breast Ultrasound Diagnosis Software

Not Applicable
Completed
Conditions
Breast Cancer
Breast Diseases
Interventions
Diagnostic Test: Reader Group Y - Session 2
Diagnostic Test: Reader Group Y - Session 1
Diagnostic Test: Reader Group X - Session 2
Diagnostic Test: Reader Group X - Session 1
Registration Number
NCT04551105
Lead Sponsor
TaiHao Medical Inc.
Brief Summary

The BR-USCAD DS Module is a computer-assisted detection and diagnosis software based on a deep learning algorithm. This retrospective, fully-crossed, multi-reader, multi-case (MRMC) study aims to compare the performances of readers without and with the aid of the Breast Ultrasound Image Reviewed with Assistance of Computer-Assisted Detection and Diagnosis System (BR-USCAD DS) in interpreting breast ultrasound images of lesions.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
16
Inclusion Criteria
  • B-mode breast ultrasound image
  • Female, age 21 or older
  • Breast lesion images acquired before a biopsy or surgery - these images were retrospectively collected with histology report.
  • Non-biopsied benign lesions with negative follow-up for a minimum of 24 months
  • At least two orthogonal views of a lesion
Exclusion Criteria
  • Breast lesion images acquired after biopsy or surgery.
  • Any breast surgeries or interventional procedures in the 12 months prior to ultrasound imaging
  • Case demonstrating administrative or technical errors
  • Multiple lesions in one 2-D ultrasound image
  • Breast ultrasound images with Doppler, elastography, or other overlays present
  • Case with less than 2-year follow-up and without biopsy confirmation

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Second session: review with CADx first and then manual reviewReader Group Y - Session 2At least 4 weeks after first session for memory washing out. Rader Group Y interpret the "Dataset A" cases in different random order without any assistance of AI first, and then interpret the "Dataset B" cases in different random order with TaiHao AI system.
First session: review with CADx first and then manual reviewReader Group Y - Session 1Reader Group Y interpret the "Dataset A" cases in different random order with TaiHao AI system first, and then interpret the "Dataset B" cases in different random order without any assistance of AI.
Second session: manual review first and then review with CADxReader Group X - Session 2At least 4 weeks after first session for memory washing out. Reader Group X interpret the "Dataset A" cases in different random order with TaiHao AI system first, and then interpret the "Dataset B" cases in different random order without any assistance of AI.
First session: manual review first and then review with CADxReader Group X - Session 1Reader Group X interpret the "Dataset A" cases in different random order without any assistance of AI first, and then interpret the "Dataset B" cases in different random order with TaiHao AI system.
Primary Outcome Measures
NameTimeMethod
Comparing the Area Under the LROC Curve10 weeks

The area under the LROC curve (AUC_LROC) on the diagnosis of benign and malignant lesions was computed and compared for Aim 1 (baseline) and Arm 2 (with BU-CAD assistance) studies.

Secondary Outcome Measures
NameTimeMethod
The Sensitivity, Specificity, PPV, and NPV Were Computed and Compared for Aim 1 (Baseline) and Arm 2 (With BU-CAD Assistance) Studies.10 weeks

The mean sensitivity, specificity, PPV, and NPV of 16 readers were calculated and compared between the aided and unaided sessions using McNemar's test.

The Reading Time Was Computed and Compared for Aim 1 (Baseline) and Arm 2 (With BU-CAD Assistance) Studies.10 weeks

Each reader's reading time of a case was automatically recorded by the BU-CAD system.

the average reading times of 16 readers with and without outlier reading times were compared between the aided and unaided sessions using the paired t-test.

Trial Locations

Locations (1)

Arlington Innovation Center: Health Research - Virginia Tech

🇺🇸

Arlington, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath